FDA cited BioLyte Laboratories for manufacturing failures and unapproved silver, CBD, and magnesium drug products.
What happened
FDA inspected BioLyte’s drug manufacturing facility in Grand Rapids, MI, from December 9 to 18, 2019 and on February 13, 2020, and reviewed the company’s January 9, 2020 response to the inspection findings. FDA also reviewed product labeling, including websites listed on the labels. FDA found failures in current good manufacturing practice (CGMP, the quality rules for drug manufacturing)—including batch testing, component identity testing, and stability data—and found that silver, pain, CBD, and magnesium products were marketed as unapproved new drugs and were misbranded (illegally labeled or marketed).
What FDA found
The company released OTC topical drugs without testing each batch for identity and strength of active ingredients, such as menthol 4%.
21 CFR 211.165(a)The company did not perform identity testing on each incoming drug component and did not validate supplier test results reported on certificates of analysis.
21 CFR 211.84(d)(1) and (2)The company lacked stability data to support the 3-year expiration date for its OTC Pain Relief drug product.
21 CFR 211.166(a)The company marketed silver, pain, CBD, and magnesium products as drugs with claims to treat wounds, infections, pain, and other conditions without FDA-approved applications.
FD&C Act sections 505(a) and 301(d), 21 U.S.C. 355(a) and 331(d)The products were misbranded, meaning FDA says their labeling or marketing violated the law.
FD&C Act section 502, 21 U.S.C. 352The Magnesium Oil Spray and CBD-labeled pain products did not meet conditions for marketing as nonprescription drugs without an approved application.
FD&C Act section 505G; 21 CFR 330.1(e)
What FDA wants
FDA tells BioLyte to correct the violations and provide detailed testing, supplier qualification, retain-sample, and stability plans, and to address the unapproved new drug and misbranding charges. No response deadline is stated in the provided letter.
Who should pay attention
- retailers and distributors selling silver, CBD, homeopathic, or magnesium products
- brands that rely on contract manufacturers’ certificates of analysis
- consumers using unapproved topical wound-care or pain products
This is a summary. Read the original letter on fda.gov.